Expansion Details
Accent Microcell Limited has finalized a turnkey agreement with Inox Wind Limited for the installation of a 4.45 MW Wind Turbine Generator. This capital expenditure represents a strategic shift towards captive renewable energy generation. The project involves the complete setup and commissioning of the turbine unit, which is slated to support the company’s manufacturing infrastructure.
Financing for this initiative will be managed through a combination of internal accruals and external borrowings, reflecting the company’s robust balance sheet and commitment to sustainable operational scaling.
Strategic Rationale
- Reduction of electricity consumption costs at existing Plant-I and Plant-II facilities
- Addressing anticipated energy requirements for Phase-I of the upcoming Plant-III
- Mitigation of grid-based power tariff volatility through captive consumption
- Improvement of operating profit margins to enhance long-term competitive edge
- Direct contribution to sustainability goals through wind-based power generation
Business Overview
Accent Microcell is a leading player in the pharmaceutical and biotechnology sector, specializing in the production of Microcrystalline Cellulose and other essential excipients. The company operates key manufacturing units in Pirana and Dahej, Gujarat, catering to both domestic and international drug formulation markets. By integrating renewable energy into its manufacturing supply chain, the company strengthens its environmental profile while ensuring a reliable power source for its precision-driven chemical processing environments.
This infrastructure upgrade supports their broader goal of industrial efficiency.
Financial Context
The company’s financial trajectory shows strong momentum, with annual net profit growing by 32.65% in the latest fiscal period. With a market capitalization of ₹1,362.1 crore, the stock has delivered a notable 98.15% return over the past year. The current Price-to-Earnings ratio stands at 31.06, trailing the broader industry average of 45.66.
Healthy operating cash flows of ₹18.64 crore provide the necessary liquidity for this capital expenditure without compromising the company's financial stability or ongoing projects.
